Differences in sensitivity to neoadjuvant chemotherapy among invasive lobular and ductal carcinoma of the breast and implications on surgery–A systematic review and meta-analysis
Open Access
- 1 December 2021
- journal article
- review article
- Published by Elsevier in The Breast
- Vol. 61, 1-10
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Research Institute
This publication has 81 references indexed in Scilit:
- Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancerBreast Cancer Research and Treatment, 2012
- Clinical and Pathological Features of Breast Cancer Associated with the Pathological Complete Response to Anthracycline-Based Neoadjuvant ChemotherapyOncology, 2011
- Neoadjuvant Chemotherapy Is Associated with Improved Survival Compared with Adjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer Only after Complete Pathologic ResponseAnnals of Surgical Oncology, 2011
- Neoadjuvant chemotherapy in ER+ HER2− breast cancer: response prediction based on immunohistochemical and molecular characteristicsBreast Cancer Research and Treatment, 2011
- The invasive lobular carcinoma as a prototype luminal A breast cancer: A retrospective cohort studyBMC Cancer, 2010
- The Relevance of Breast Cancer Subtypes in the Outcome of Neoadjuvant ChemotherapyAnnals of Surgical Oncology, 2010
- Variations in Gene Expression and Response to Neoadjuvant Chemotherapy in Breast CarcinomaCancer Investigation, 2009
- High rates of breast conservation for large ductal and lobular invasive carcinomas combining multimodality strategiesBritish Journal of Cancer, 2008
- Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSFBreast Cancer Research and Treatment, 2006
- Surgical Procedures After Neoadjuvant Chemotherapy in Operable Breast Cancer: Results of the GEPARDUO TrialAnnals of Surgical Oncology, 2006